Helicobacter hypothesis for idiopathic parkinsonism: Before and beyond

Helicobacter

Volumn 13, Issue 5, 2008, Pages 309-322

  Dobbs, R John ^a,b   Dobbs, Sylvia M ^a,b   Weller, Clive ^a   Charlett, André ^a,c   Bjarnason, Ingvar T ^b   Curry, Alan ^c   Ellis, David S ^d   Ibrahim, Mohammad A A ^b   McCrossan, Maria V ^d   O'Donohue, John ^b   Owen, Robert J ^c   Oxlade, Norman L ^a   Price, Ashley B ^e   Sanderson, Jeremy D ^f   Sudhanva, Malur ^b   Williams, John ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e ST MARK S HOSPITAL   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aetiology; Helicobacter; Mitochrondria; Parkinson's Disease; Pathogenesis; Small intestinal baterial overgrowth; Virus

Indexed keywords

INTERLEUKIN 6; MINOCYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DETECTION; BACTERIAL OVERGROWTH; BRADYKINESIA; CONSTIPATION; DETERIORATION; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DISEASE PREDISPOSITION; ERADICATION THERAPY; HELICOBACTER; HISTORY OF MEDICINE; HUMAN; HYPOKINESIA; HYPOTHESIS; IDIOPATHIC DISEASE; INFLAMMATION; INTESTINE TRANSIT TIME; NERVE DEGENERATION; PARKINSONISM; PRIORITY JOURNAL; PROBABILITY; REVIEW; RIGIDITY; UNITED KINGDOM; UREA BREATH TEST;

ANIMALS; HELICOBACTER INFECTIONS; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; PARKINSON DISEASE;

BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER PYLORI; PARKINSONIA;

EID: 49749088770     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00622.x     Document Type: Review

References (101)

1. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones 1817.
2. Ordenstein L. Sur la Paralysie Agitante et la Sclérose en Plaque Géneralisée. Paris: E Martinet, 1867.
3. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain and its relation to diseases of the extrapyramidal system. Wien Klin Wschr 1960 38: 1236 1239.
4. Schwab RS, England AC Jr, Poskanzer C, et al. Amantadine in the treatment of Parkinson's disease. JAMA 1969 208: 1168 70.
5. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983 1: 1273 5.
6. Strang RR. The association of gastro-duodenal ulceration with Parkinson's disease. Med J Austr 1965 52: 842 3.
7. Szabo S. Dopamine disorder in duodenal ulceration. Lancet 1979 ii: 880 2.
8. Altschuler E. Gastric Helicobacter pylori infection as a cause of idiopathic Parkinson's disease and non-arteric anterior optic ischaemic neuropathy. Med Hypotheses 1996 47: 413 4.
9. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 24: 197 211.
10. Lang AE, Lozano AM. Parkinson's disease. New Eng J Med 1998 339: 1044 53.
11. Zimprich A, Biskup S, Lietner P, et al. Mutations in the LRRK2 gene cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004 44: 601 7.
12. Calne DB. Parkinson's disease is not one disease. Parkinsonism Related Disord 2001 7: 3 7.
13. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992 32 (Suppl 125 7.
14. Liu B, Gao H-M, Hong J-S. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: Role of neuroinflammation. Environ Health Perspect 2003 111: 1065 73.
15. Markopoulou K, Langston JW. Candidate genes and Parkinson's disease. Where to next? Neurology 1999 53: 1382 3.
16. Charlett A, Dobbs RJ, Weller C, Dobbs SM. Stasis in the gut: The source of xenobiotic in idiopathic parkinsonism. Eur J Clin Pharmacol 1997 52 (Suppl 168.
17. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001 57: 456 62.
18. Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995 346: 861 4.
19. Kupsky WJ, Grimes MM, Sweeting J, Bectsch R, Cote LJ. Parkinson's disease and megacolon: Hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987 37: 1253 5.
20. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003 2: 107 16.
21. Dobbs SM, Dobbs RJ, Weller C, Charlett A. Link between Helicobacter pylori infection and idiopathic parkinsonism. Med Hypotheses 2000 55: 93 8.
22. Dobbs RJ, Dobbs SM, Weller C, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the aetiology and pathogenesis of idiopathic parkinsonism. Part 1: Eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 2005 10: 267 75.
23. Bjarnason IT, Charlett A, Dobbs RJ, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the aetiology and pathogenesis of idiopathic parkinsonism. Part 2: Response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomised, double-blind, placebo-controlled efficacy study. Helicobacter 2005 10: 276 87.
24. Dobbs SM, Dobbs RJ, Charlett A, et al. Helicobacter in idiopathic parkinsonism: A template for intervention in the role of inflammation in neuropsychiatric disease. Helicobacter 2006 11: 371.
25. Dobbs SM, Dobbs RJ, Charlett A, Weller C, Bjarnason IT. Differential effect of Helicobacter eradication on facets of idiopathic parkinsonism: Explanation for predominantly hypokinetic or rigid syndromes. Helicobacter 2007 12: 423.
26. Dobbs RJ, Dobbs SM, Charlett A, et al. Lymphopenia in idiopathic parkinsonism and spouses of probands as a clue to an infectious environmental insult. J Neuroimmunol 2006 178 (Suppl. 1 198 9.
27. Weller C, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, Bjarnason IT. Role of chronic infection and inflammation in the gastrointestinal tract in the aetiology and pathogenesis of idiopathic parkinsonism. Part 3: Predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter 2005 10: 288 97.
28. Ellis D, Curry A, Dobbs RJ, et al. Duodenal enterocyte mitochondrial involvement and abnormal bowel function in idiopathic parkinsonism. In: Hanin I, Windisch M, Poewe W, Fisher A: New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007. Bologna: Medimond S.r.l., 2007 269 72.
29. Drumm B, Perez Perez GI, Blaser MJ, Sherman PM. Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med 1990 322: 358 63.
30. de la Fuente-Fernandez R, Calne DB. Evidence for environmental causation of Parkinson's disease. Parkinsonism Related Disorders 2002 8: 235 41.
31. Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW. Parkinsonism: Siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand 1999 99: 26 35.
32. Ben-Shlomo Y. The epidemiology of Parkinson's disease. Bailliere's Clin Neurol 1997 6: 55 67.
33. Weller C, Oxlade NL, Charlett A, et al. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol Med Microbiol 2005 7: 129 35.
34. Perry VH. Persistent pathogens in the parenchyma of the brain. J Neurovirol 2000 6 (Suppl. 1 86 9.
35. Watkins AD. Perceptions, emotions and immunity: An integrated homeostatic network. Q J Med 1995 88: 283 94.
36. Gerlach M, Riederer P, Youdim MBH. Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Adv Neurol 1996 69: 177 94.
37. 1 reductase (Complex I) deficiency in Parkinson's disease. J Neurochem 1990 55: 2142 5.
38. Oeretel WH, Bandmann O, Eichhorn T, Gasser T. Peripheral markers in Parkinson's disease. An overview. Adv Neurol, 1996 69: 283 91.
39. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996 40: 663 71.
40. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Reiderer P. Parkinsonism in HIV dementia. J Neural Transm 2002 109: 767 75.
41. Lewin PK, Edwards V. Mitochondrial inclusions in neurons of Creutzfeldt-Jakob-like disease. Lancet 1991 337: 236 7.
42. Wooten GE, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Parker WD. Maternal inheritance in Parkinson's disease. Ann Neurol 1997 41: 265 8.
43. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988 85: 6465 7.
44. Andersson SG, Karlberg O, Canbäck B, Kurland CG. On the origin of mitochondria: A genomics perspective. Philos Trans R Soc London B Biol Sci 2003 358: 165 77 discussion 177-9.
45. Marshall DG, Dundon WG, Beesley SM, Smyth CJ. Helicobacter pylori - A conundrum of genetic diversity. Microbiology 1998 144: 2925 39.
46. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumour necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994 172: 151 4.
47. El-Omar EM. The importance of interleukin 1β in Helicobacter pylori associated disease. Gut 2001 48: 743 7.
48. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003 124: 1193 201.
49. Dobbs SM, Dobbs RJ, Charlett A, et al. A direct, or surrogate, not necessarily unique, role for Helicobacter infection in pathogenesis of idiopathic parkinsonism: Analogy and contrast with gastric cancer. In: Hanin I, Windisch M, Poewe W, Fisher A: New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007. Bologna: Medimond S.r.l., 273 6.
50. Krüger R, Hardt C, Tschentscher F, et al. Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. J Neural Transm 2000 107: 553 62.
51. Schulte T, Schöls L, Müller T, Woitalla D, Berer K, Krüger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci Lett 2002 326: 70 2.
52. McGeer PL, Yasojima K, McGeer EG. Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease. Neurosci Lett 2002 326: 67 9.
53. Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kuno S. Influence of interleukin-1β gene polymorphisms on age-at-onset of sporadic Parkinson's disease. Neurosci Lett 2000 284: 73 6.
54. Nishimura M, Mizuta I, Mizuta E, et al. Tumour necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci Lett 2001 311: 1 4.
55. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976 2: 1525 36.
56. Charlett A, Dobbs RJ, Purkiss AG, et al. Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand 1998 97: 77 85.
57. Dobbs SM, Charlett A, Dobbs RJ, Weller C. Does the protective effect of tobacco smoking in idiopathic parkinsonism reside in its laxative action. Naunyn Schmiedebergs Arch Pharmacol 1998 358 (Suppl. 2 479.
58. Murray LJ, McCrum EE, Evans AE, Bamford KB. Epidemiology of Helicobacter pylori infection amongst 4742 randomly selected subjects from Northern Ireland. Int J Epidemiol 1997 26: 880 7.
59. Charlett A, Dobbs RJ, Dobbs SM, Weller C, Peterson DW. Parkinsonism: Differential age-trend in Helicobacter pylori antibody. Alimentary Pharmacol Therapeutics 2000 14: 1199 205.
60. Charlett A, Purkiss AG, Dobbs SM, Dobbs RJ, Weller C, Peterson DW. Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999 100: 34 41.
61. Weller C, Nicholson PW, Dobbs SM, Bowes SG, Purkiss A, Dobbs RJ. Reduced axial rotation in the spouses of sufferers from idiopathic Parkinsonism. Age Ageing 1992 21: 189 94.
62. Kirollos C, O. 'Neill CJA, Dobbs RJ, et al. Quantification of the cardinal signs of parkinsonism and of associated disability in spouses of sufferers. Age Ageing 1993 22: 20 6.
63. Kirollos C, Charlett A, O. 'Neill CJA, et al. Objective measurement of activation of rigidity: Diagnostic, pathogenetic and therapeutic implications in parkinsonism. Br J Clin Pharmacol 1996 41: 557 64.
64. O. 'Neill CJA, Richardson MD, Charlett A, et al. Could seborrhoeic dermatitis be implicated in the pathogenesis of parkinsonism? Acta Neurol Scand 1994 89: 252 7.
65. Purkiss AG, Charlett A, Wright DJ, et al. Associations of immunoglobulins, IgG, IgA and IgM, with treatment in those with diagnosed parkinsonism, and with parkinsonian-like postural abnormality in those without. Br J Clin Pharmacol 1998 41: 457 8.
66. Purkiss AG, Charlett A, Weller C, Dobbs SM, Dobbs RJ. Association of serum immunoglobulin subclasses IgA1 and IgA2 with facets of parkinsonism. Br J Clin Pharmacol 1998 45: 207.
67. Charlett A, Dobbs SM, Dobbs RJ, Peterson DW, Weller C. Could antibodies to Helicobacter pylori urease explain the facets of parkinsonism quantified in subjects who have and have not passed the diagnostic threshold? Br J Clin Pharmacol 1999 48: 888.
68. Charlett A, Dobbs RJ, Dobbs SM, Weller C, Peterson DW. Does Helicobacter pylori account for increase in serum interleukin-6 and tumour necrosis factor-α with age and interleukin-6 and cortisol with parkinsonism? Br J Pharmacol 1999 127 (Suppl 79.
69. Charlett A, Weller C, Oxlade N, Dobbs SM, Dobbs RJ. Systemic cortisol response to Helicobacter pylori vacuolating toxin in parkinsonism and controls. Br J Clin Pharmacol 2000 131: 220.
70. Dobbs RJ, Dobbs SM, Charlett A, Weller C. Downward shift in serum IgM with Helicobacter pylori seropositivity. J Infection 2000 41: 240 4.
71. Charlett A, Dobbs RJ, Weller C, Dobbs SM, Peterson DW. Evidence for autoimmunity triggered by Helicobacter pylori in idiopathic parkinsonism. Br J Clin Pharmacol 2000 49: 506 7.
72. Oxlade N, Charlett A, Weller C, Dobbs RJ, Dobbs SM. Discriminant index for seborrhoeic dermatitis based on antibody profile against Helicobacter pylori. Brit J Clin Pharmacol 2000 49: 506.
73. Drossman DA, ed. The Functional Gastrointestinal Disorders. Diagnosis, Pathology, and Treatment - A Multinational Consensus. Boston, MA: Little, Brown and Co., 1994.
74. high regulatory T-cells suppress memory T-cell responses to Helicobacter pylori in infected individuals. Infect Immun 2003 71: 1755 62.
75. Schmees C, Prinz C, Treptau T, et al. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase. Gastroenterology 2007 132: 1820 33.
76. Nilsson H-O, Pietroiusti A, Gabrielli M, Assunta Zocco M, Gasbarrini G, Gasbarrini A. Helicobacter pylori and extragastric diseases - Other Helicobacters. Helicobacter 2005 10 (Suppl. 1 54 65.
77. McGeer P, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1998 38: 1285 9.
78. Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc Natl Acad Sci USA 1997 94: 7531 6.
79. Mogi M, et al. Interleukin-1-beta, interleukin-6, epidermal growth-factor-alpha and transforming growth-factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Letts 1994 180: 147 50.
80. Mogi M, et al. Interleukin (IL)-1-beta, IL-2, IL-4, Il-6 and transforming growth-factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Letts 1996 211: 13 6.
81. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005 28: 2665 74.
82. Chiba S, et al. A correlation study between serum adenosine-deaminase activities and peripheral lymphocyte subsets in Parkinson's disease. J Neurol Sci 1995 132: 170 3.
83. + T cells in peripheral blood. Acta Neurol Scand 1994 90: 160 6.
84. Bas J, Calopa M, Mestre M, et al. Lymphocyte populations in Parkinson's disease and in rat models of Parkinsonism. J Neuroimmunol 2001 113: 146 52.
85. Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 2001 58: 1580 3.
86. + T cells are increased in patients with Parkinson's disease. J Neurol Sci 1994 121: 39 45.
87. Fiszer U, et al. Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson's disease. J Neurol Sci 1996 139: 66 70.
88. Poupard A, Emile J. Autoimmunity in Parkinson's disease. In: Hassler RG Christ JF, eds. Parkinson-Specific Motor and Mental Disorders. Role of the Pallidum: Pathophysiological Biochemical and Therapeutic Aspects. Adv Neurol 40. New York: Raven Press, 1984 307 14.
89. McRae A, Degueurce A, Gottfries C-G, Karlsson I, Svennerholm L, Dahlström A. Antibodies in the CSF of a Parkinson patient recognizes neurons in rat mesencephalic regions. Acta Physiol Scand 1986 126: 313 5.
90. Chen S, Le WD, Xie WJ, et al. Experimental destruction of substantia nigra initiated by Parkinson's disease immunoglobulins. Arch Neurol 1998 55: 1075 80.
91. Dahlström A, Wigander A, Lundmark K, Gottfries C-G, Carvey PM, McRae A. Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases using defined neuronal cultures. J Neural Transm 1990 29 (Suppl 195 206.
92. Defazio G, Dal Toso R, Benvegnù D, Minozzi MC, Cananzi AR, Leon A. Parkinson serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res 1994 633: 206 12.
93. He Y, Le W-D, Appel SH. Role of Fcγ receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 2002 176: 322 7.
94. Karlsen NR, Reinvang I, Frøland SS. Slowed reaction time in asymptomatic HIV-positive patients. Acta Neurol Scand 1992 86: 242 6.
95. Berger JR, Arendt G. HIV dementia: The role of the basal ganglia and dopaminergic systems. J Psychopharmacol 2000 14: 214 21.
96. Bateman PA, Miller AR, Sedgwick PM, Griffin GE. Autonomic denervation in jejunal mucosa of homosexual men infected with HIV. AIDS 1991 5: 1247 52.
97. Kwon H-J, Kang J-O, Cho S-H, et al. Presence of human mycoplasma DNA in gastric tissue samples from Korean chronic gastritis patients. Cancer Sci 2004 95: 311 5.
98. Bower JH, Ahlskog JE, Maraganone DM, Rocca WA, Peterson BJ. Immunologic diseases, anti-inflammatory drugs and Parkinson's disease: A case control study. Neurology 2006 67: 494 6.
99. Tsui JK, Calne DB, Wang Y, Schulzer M, Marion SA. Occupational risk factors in Parkinson's disease. Can J Public Health 1999 90: 334 7.
100. Tomas-Camardiel M, Rite I, Herrera AJ, et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 2004 16: 190 201.
101. Bowes S, Dobbs RJ, Henley M, et al. Objective evidence for tolerance, against a back-ground of improvement during maintenance therapy with controlled release levodopa/carbidopa. Eur J Clin Pharmacol 1992 43: 483 9.